Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Steven O'Day Biography and Net Worth

Insider of Agenus

Dr. Steven O’Day serves as Agenus’ Chief Medical Officer. He is responsible for leading the expansion of the company’s presence in the I-O field. A pioneer in CTLA-4 inhibition, Steven played key roles in the advancement of cancer therapies Yervoy and Opdivo, and has been the principal investigator in more than 200 clinical trials. Prior to joining Agenus, he was Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center, and Director of the Melanoma and Cutaneous Oncology Research Center. Steven was a visiting scholar in philosophy and medical ethics at Oxford, received his MD from Johns Hopkins, and was a Fellow at the Dana Farber/Harvard Cancer Center.

How do I contact Steven J. O'Day?: The corporate mailing address for Mr. O'Day and other Agenus executives is 3 FORBES ROAD, LEXINGTON MA, 02421. Agenus can also be reached via phone at (781) 674-4400 and via email at [email protected]. Learn More on Steven J. O'Day's contact information.
Has Steven J. O'Day been buying or selling shares of Agenus?: Steven J. O'Day has not been actively trading shares of Agenus in the last ninety days. Most recently, Steven J. O'day sold 1,933 shares of the business's stock in a transaction on Thursday, January 6th. The shares were sold at an average price of $61.20, for a transaction totalling $118,299.60. Learn More on Steven J. O'Day's trading history.
Who are Agenus' active insiders?: Agenus' insider roster includes Garo Armen (CEO), Christine Klaskin (Insider), and Steven O'Day (Insider). Learn More on Agenus' active insiders.
Are insiders buying or selling shares of Agenus?: During the last twelve months, Agenus insiders bought shares 9 times. They purchased a total of 47,628 shares worth more than $893,492.60. The most recent insider tranaction occured on February, 15th when insider Garo H Armen bought 25,000 shares worth more than $325,000.00. Insiders at Agenus own 4.8% of the company. Learn More about insider trades at Agenus.
Information on this page was last updated on 2/15/2024.

Steven J. O'Day Insider Trading History at Agenus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/6/2022	Sell	1,933	$61.20	$118,299.60

Steven J. O'Day Buying and Selling Activity at Agenus

Agenus Company Overview

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $4.91

$4.86

$6.14

50 Day Range

MA: $12.04

$5.40

$18.56

2 Week Range

Now: $4.91

$4.86

$42.60

Volume

1,052,807 shs

Average Volume

577,960 shs

Market Capitalization

$102.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Claim Your Complimentary Bitcoin Reward

From Crypto Swap Profits | Ad

Secure Your Spot Now